Glucotrack (Nasdaq:GCTK) today announced the results from the first-in-human clinical study of its long-term continuous blood glucose monitor (CBGM). Rutherford, New Jersey-based Glucotrack shared findings at the American Diabetes Association’s 85th Scientific Sessions in Chicago. (See all the biggest stories out of ADA 2025 here.) Glucotrack’s device features no on-body external component. The company designed […]
Implants
Senseonics lays out hopes for next-gen CGM commercial timelines
Senseonics (NYSE:SENS) has offered some insight into its plans for its next-generation implantable continuous glucose monitors (CGMs). The maker of the Eversense 365 year-long implantable CGM hosted an analyst event during the American Diabetes Association’s 85th Scientific Sessions in Chicago this past weekend. At that event, the company touched on the commercial strategy for Eversense […]
Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy
A new study has demonstrated proof of concept for a Biolinq continuous sensor in preventing muscle loss during GLP-1 therapy. Investigators presented findings as a late-breaking poster at the American Diabetes Association’s 85th Scientific Sessions in Chicago. Using a DNA-based bioreceptor (aptamer), Biolinq designed its sensor to detect phenylalanine, an essential amino acid. Released from […]
A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
Glucotrack (Nasdaq:GCTK) believes it can tap into a diabetes market that includes millions of people who aren’t being served completely. That’s according to the company’s Chief Scientific Officer, Mark Tapsak, who gave a presentation on the company’s long-term implantable continuous blood glucose monitor (CBGM) as part of the American Diabetes Association’s 85th Scientific Sessions’ “Innovation […]
Glucotrack to effect a reverse stock split
Glucotrack (Nasdaq:GCTK) announced that it plans to effect a 1-for-60 reverse stock split of its issued and outstanding common stock. Rutherford, New Jersey-based Glucotrack — maker of a long-term implantable continuous blood glucose monitor (CBGM) — intends for the split to go into effect when the market opens on Monday, June 16, 2025. Under the terms […]
SpyGlass Pharma raises $75M for drug delivery platform
SpyGlass Pharma announced today that it closed a $75 million Series D financing round to support its drug delivery platform. Sands Capital led the financing round, with Gilde Healthcare also joining. Existing investors New Enterprise Associates (NEA), RA Capital, Vensana Capital, Samsara BioCapital and Vertex Ventures HC participated. The company said funds support its drug […]
Vivani files with SEC to spin off neurostim business, focus on drug delivery implants
Vivani Medical (Nasdaq:VANI) announced today that it filed a Form 10 registration statement with the SEC to spin off its neurostimulation unit. The company said earlier this year that it plans to spin off Cortigent, a division that develops brain implants. The company wants to create two focused companies dedicated to driving current and future […]
Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
Elixir Medical announced three-year results from a large randomized controlled trial of its DynamX coronary bioadaptor system. The 445-patient BIOADAPTOR trial compares DynamX to the standard of care Medtronic Resolute Onyx drug-eluting stent (DES). It took place across 34 centers in Japan, Europe and New Zealand. Data — shared this week at EuroPCR 2025 in […]
Senseonics closes public offering, private placement with Abbott
Senseonics (NYSE:SENS) announced that it closed its previously announced public offering and private placement with Abbott. Last week, the long-term continuous glucose monitor maker said it commenced an underwritten public offering of common stock worth $50 million. At the same time, it entered into a securities purchase agreement with another CGM maker — Abbott. Under […]
Senseonics opens $50M public offering, $25M private placement with Abbott
Senseonics (NYSE:SENS) announced today that it commenced an underwritten public offering of common stock worth $50 million. The long-term implantable continuous glucose monitor (CGM) maker expects to grant underwriters a 30-day option to purchase up to an additional 15% of the total number of shares of stock offered in the public offering. All shares to be […]
